- Home
- ATYR vs EDD Comparison
ATYR vs EDD Comparison
Compare ATYR & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATYR
- EDD
- Stock Information
- Founded
- ATYR 2005
- EDD 2007
- Country
- ATYR United States
- EDD United States
- Employees
- ATYR N/A
- EDD N/A
- Industry
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- EDD Finance Companies
- Sector
- ATYR Health Care
- EDD Finance
- Exchange
- ATYR Nasdaq
- EDD Nasdaq
- Market Cap
- ATYR 330.7M
- EDD 307.8M
- IPO Year
- ATYR 2015
- EDD N/A
- Fundamental
- Price
- ATYR $3.68
- EDD $4.82
- Analyst Decision
- ATYR Strong Buy
- EDD
- Analyst Count
- ATYR 6
- EDD 0
- Target Price
- ATYR $18.60
- EDD N/A
- AVG Volume (30 Days)
- ATYR 1.9M
- EDD 254.3K
- Earning Date
- ATYR 03-13-2025
- EDD 01-01-0001
- Dividend Yield
- ATYR N/A
- EDD 7.52%
- EPS Growth
- ATYR N/A
- EDD N/A
- EPS
- ATYR N/A
- EDD N/A
- Revenue
- ATYR $235,000.00
- EDD N/A
- Revenue This Year
- ATYR $1,387.23
- EDD N/A
- Revenue Next Year
- ATYR $873.22
- EDD N/A
- P/E Ratio
- ATYR N/A
- EDD N/A
- Revenue Growth
- ATYR N/A
- EDD N/A
- 52 Week Low
- ATYR $1.42
- EDD $4.22
- 52 Week High
- ATYR $4.66
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- ATYR 50.20
- EDD 55.15
- Support Level
- ATYR $2.98
- EDD $4.71
- Resistance Level
- ATYR $4.32
- EDD $4.91
- Average True Range (ATR)
- ATYR 0.36
- EDD 0.04
- MACD
- ATYR 0.03
- EDD 0.00
- Stochastic Oscillator
- ATYR 60.37
- EDD 52.50
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.